Oncotarget

Research Papers:

Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis

Hao Hu, Wei Qing Lin, Qian Zhu, Xiong Wen Yang, Hai Dong Wang and Yu Kang Kuang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:81090-81098. https://doi.org/10.18632/oncotarget.13191

Metrics: PDF 2925 views  |   HTML 2757 views  |   ?  


Abstract

Hao Hu1,*, Wei Qing Lin2,6,*, Qian Zhu3,*, Xiong Wen Yang1, Hai Dong Wang4, Yu Kang Kuang5

1Department of Thoracic Surgery, Medical College of Nanchang University, Nanchang, 330006, China

2Department of Integrated Chinese and Western Medicine, Medical College of Nanchang University, Nanchang, 330006, China

3Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangdong, 510060, China

4Department of General Surgery, Medical College of Nanchang University, Nanchang, 330006, China

5Department of Thoracic Surgery, Medical College of Nanchang University, Jiangxi Province Tumor Hospital, Nanchang, 330006, China

6Department of Integrated Chinese and Western Medicine, Jiangxi Province People's Hospital, Nanchang, 330006, China

*These authors contributed equally to this work

Correspondence to:

Yu Kang Kuang, email: [email protected]

Keywords: meta-analysis, crizotinib, anaplastic lymphoma kinase, non-small cell lung cancer

Received: April 23, 2016     Accepted: October 31, 2016     Published: November 07, 2016

ABSTRACT

Background: Crizotinib show a promising efficacy in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). However, differences in efficacy for first- and second-line crizotinib are unclear.

Results: The pooled overall response rate and progression-free survival were 65% and 9.38 months, respectively. In the subgroup analysis, first-line crizotinib showed a higher trend of overall response rate and longer trend of progression-free survival although there was no statistical difference between first-line and second-line crizotinib (74%, 11.28 months vs. 65%, 8.12 months, respectively; fixed effects model). Moreover, overall response rate between Asians and Caucasians were similar (67% and 66%, respectively; fixed effects model).

Materials and Methods: A comprehensive search of MEDLINE, EMBASE, WEB OF SCIENCE and the COCHRANE databases from their inception to February 2016 was performed to identify clinical trials in English-language journals. Pooled overall response rate, progression-free survival and differences between first- and second-line crizotinib were estimated. Moreover, overall response rate between Asians and Caucasians were also estimated.

Conclusions: First-line crizotinib may more effective than second-line crizotinib for patients with locally advanced or metastatic ALK-positive NSCLC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13191